{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}],"title":"Discontinuations for any reason"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}],"title":"Discontinuation for Disease Progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Discontinuation for Corneal or other ocular toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Discontinuation for Physician/Patient choice"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Discontinuation for other reason"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Number of participants who discontinued treatment with BLENREP by reason.","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Treatment Characteristics: Discontinuation of BLENREP Treatment","type":"PRIMARY","unitOfMeasure":"Participants"}